Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04257617 · ClinicalTrials.gov registry record · Phase 1

A Trial of ZL-1201 in Subjects With Advanced Cancer

A Phase 1 study of Advanced Cancer, sponsored by Zai Lab (Shanghai) Co..

Completed
Registry status
Phase 1
Development phase
37
Enrollment target
7
Study locations

NCT04257617: Completed Phase 1 study of Advanced Cancer, sponsored by Zai Lab (Shanghai) Co..

NCT04257617 is a Phase 1 study of Advanced Cancer that has completed, run by Zai Lab (Shanghai) Co.. The registered enrollment target is 37 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (85% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04257617, a Phase 1 study of Advanced Cancer, has completed, sponsored by Zai Lab (Shanghai) Co..

COMPLETED
Registry status
Phase 1
Development phase
37 participants
Enrollment target
7
Study locations

Study Summary

First in Human, Phase I Trial of ZL-1201 in Subjects with Advanced Cancer

Primary Outcome

Incidence of Treatment-Emergent Adverse Events as Assessed by CTCAE v5.0

Conditions Studied

Advanced Cancer

Interventions

  • DRUG ZL-1201

Study Locations (7)

Arizona

  • US2004 - Phoenix

Florida

  • US2005 - Jacksonville

Minnesota

  • US2001 - Rochester

Missouri

  • US2003 - St Louis

New York

  • US2002 - New York

Chongqing Municipality

  • CN1003 - Chongqing

Zhejiang

  • CN1002 - Hangzhou

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2020-05-11
Est. Completion 2023-01-19
Phase Phase 1
Zai Lab (Shanghai) Co.

5 total trials

What the finished NCT04257617 record still lists

NCT04257617 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which ZL-1201 is the first listed.

NCT04257617 lists 7 locations in 7 states (Arizona, Florida, Minnesota).

Frequently Asked Questions

What is clinical trial NCT04257617 about?

NCT04257617 is a clinical study titled "A Trial of ZL-1201 in Subjects With Advanced Cancer". First in Human, Phase I Trial of ZL-1201 in Subjects with Advanced Cancer

What is the current status of trial NCT04257617?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2020-05-11. Estimated completion is 2023-01-19.

What conditions does trial NCT04257617 study?

This clinical trial studies the following conditions: Advanced Cancer.

What interventions are being tested in trial NCT04257617?

The interventions under investigation include: ZL-1201 (DRUG).

Who is sponsoring clinical trial NCT04257617?

This trial is sponsored by Zai Lab (Shanghai) Co., which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04257617 being conducted?

This trial has 7 study locations across Arizona, Florida, Minnesota, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04257617's enrollment target sits among peer trials

37 94th of 122 higher than 29 of 122 other Advanced Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02800486 · 37 participants · Phase 2

    Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

  • NCT03173937 · 37 participants · Phase 1

    Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

  • NCT03295227 · 37 participants · Phase 1

    Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

  • NCT03401047 · 37 participants · Early Phase 1

    Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04257617, the US trial registry maintained by the National Library of Medicine. NCT04257617 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.